摘要
To the Editor： Allogeneic hematopoietic siena cell transplantation （aLIo-HSCT） is a curative therapy for patients with acute myelogenous letikemia （A M L） due to the intensive conditioning chemoradiotherapy and the effect of graft-versus-leukemia （GVL）. An isolated extramedullary （EM） relapse of acute leukemia （AL） is a rare occurrence observed more commonly after allo-HSCT rather than following convemional chemotherapy alone.
To the Editor： Allogeneic hematopoietic siena cell transplantation （aLIo-HSCT） is a curative therapy for patients with acute myelogenous letikemia （A M L） due to the intensive conditioning chemoradiotherapy and the effect of graft-versus-leukemia （GVL）. An isolated extramedullary （EM） relapse of acute leukemia （AL） is a rare occurrence observed more commonly after allo-HSCT rather than following convemional chemotherapy alone.
